Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.
A Randomized, Double-blind, Parallel Controlled Phase III Study of Gentuximab Injection Combined With Paclitaxel Injection Versus Placebo Combined With Paclitaxel Injection for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
This PHASE3 trial investigates Adenocarcinoma of Stomach and is currently ongoing. Changchun GeneScience Pharmaceutical Co., Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Feb 2025 — Present [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE3
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changchun GeneScience Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .